5 completed, 2 active not recruiting, 1 terminated. 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Active not recruiting 2, Terminated 1 |
Follow Neflamapimod: new trials by email Literature Review of Neflamapimod trials Research Report on Neflamapimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia Neflamapimod, Placebo - Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Phase 2 | Active not recruiting | EIP Pharma Inc | 20 | 2025-10-02 | 2026-07-06 |
| A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke Neflamapimod, Placebo - Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke | Phase 2 | Active not recruiting | EIP Pharma Inc | 90 | 2025-06-20 | 2026-07-08 |
| A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies neflamapimod - Dementia With Lewy Bodies (DLB) | Phase 2 | Completed | EIP Pharma Inc | 26 | 2024-10-16 | 2026-07-08 |
| RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies Neflamapimod, Placebo - Dementia With Lewy Bodies | Phase 2 | Completed | EIP Pharma Inc | 159 | 2023-05-01 | 2026-09-03 |
| Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies Neflamapimod - Dementia With Lewy Bodies (DLB) | Phase 2 | Completed | EIP Pharma Inc | 91 | 2019-09-30 | 2023-06-29 |
| Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease neflamapimod, Placebo - Huntington Disease | Phase 2 | Terminated | EIP Pharma Inc | 15 | 2019-07-08 | 2022-04-06 |
| Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients VX-745, placebo - Alzheimer Disease | Phase 2 | Completed | University Hospital, Toulouse | 34 | 2018-10-08 | 2023-06-22 |
| Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease neflamapimod, placebo - Alzheimer Disease | Phase 2 | Completed | EIP Pharma Inc | 161 | 2017-12-29 | 2021-10-27 |
Lewy Body Disease (3) · Alzheimer Disease (2) · Aphasia (1) · Aphasia, Primary Progressive (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Dementia (1) · Frontotemporal Dementia (1) · Huntington Disease (1) · Ischemic Stroke (1) · Language Disorders (1) · Mental Disorders (1) · Nervous System Diseases (1) · Neurocognitive Disorders (1) · Neurodegenerative Diseases (1)
EIP Pharma Inc (7) · University Hospital, Toulouse (1)
United Kingdom (4) · United States (4) · Netherlands (3) · France (2) · Australia (1) · Czechia (1) · Denmark (1)
John Alam, MD (3)
PMID 33974419, PMID 38706271, PMID 34044875, PMID 36130946, PMID 37657939, PMID 41287056
2023 (1), R01AG080536 (1)